BioWorld

Jan. 25, 2006

View Archived Issues

ImClone Considering Sale; Erbitux Growth Continues

Despite a market cap of close to $3 billion and a 58 percent increase in Erbitux revenues in 2005, ImClone Systems Inc. is exploring strategic options that could include the sale of the company. (BioWorld Today) Read More

Public Placement Nets $30M For Tercica's Increlex Work

Read More

Curis, Genentech Stumble In Phase I Trial Of Cancer Drug

Read More

VC Financing Steady In 2005; Investors Favoring Late Stage

Read More

Other News To Note

Read More